San Diego-based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug marketplace in February soon after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March the